⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14768464 | 1.00 | — | — | |
| SCHEMBL13744990 | 1.00 | — | — | |
| SCHEMBL27089783 | 0.93 | ADH1B (0.33) | — | |
| SCHEMBL18458215 | 0.89 | ADH1B (0.32) | — | |
| SCHEMBL13397343 | 0.89 | — | — | |
| SCHEMBL23178016 | 0.87 | ADH1C (0.35) | — | |
| SCHEMBL25691939 | 0.85 | TRPA1 (0.35) | — | |
| Methyl Alcohol SCHEMBL28023379 | 0.83 | CCR2 (0.31) | — | |
| SCHEMBL19608612 | 0.81 | SPHK1 (0.31) | — | |
| SCHEMBL10093885 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| US-20210395243-A1 | PESTICIDAL COMPOUNDS | BASF SE (DE) | 2021-12-23 | — | — | US | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-10646463-B2 | Treatment for tumors driven by metabolic dysfunction | SYNDEVRX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190151353-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2019-05-23 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9682991-B2 | Tricyclic compounds for use as kinase inhibitors | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2017-06-20 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20130065883-A1 | Triazolo [4, 5- B] Pyridin Derivatives | Centro Nacional de Investigaceiones Oncologicas (CNIO) (ES) | 2013-03-14 | — | — | US | disclosed |
| US-20130065881-A1 | Tricyclic Compounds for Use as Kinase Inhibitors | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (ES) | 2013-03-14 | — | — | US | disclosed |